1-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine | 404586-53-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: 1-ethyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
• 英文别名: 1-ethylpyrazolo[3,4-d]pyrimidin-4-amine
• CAS: 404586-53-4
• 化学式: C₇H₉N₅
• mdl: MFCD17270455
• 分子量: 163.182
• InChiKey: ZKQQZCHGRXLMOI-UHFFFAOYSA-N

物化性质

• 沸点：
  354.9±22.0 °C(Predicted)
• 密度：
  1.49±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.285
• 拓扑面积：
  69.6
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES À UTILISER EN TANT QU'INHIBITEURS DE KINASES RET
  申请人：CANCER RES TECH LTD

  公开号：WO2017178845A1

  公开（公告）日：2017-10-19

  The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, X1, X2, X3, X4, integer a and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.

  本发明涉及作为RET（重排基因转位）激酶酶活性抑制剂的I式化合物：其中HET、X1、X2、X3、X4、整数a和R3各自如本文所定义。本发明还涉及制备这些化合物的方法，包括它们的药物组合物，以及它们在治疗增殖性疾病（如癌症）以及其他涉及RET激酶活性的疾病或病况中的用途。
• Stem Cell Culture Methods
  申请人：Adams David Roger

  公开号：US20120202287A1

  公开（公告）日：2012-08-09

  The invention provides methods for reversibly inhibiting stem cell differentiation wherein a compound of formula (I) is contacted with a stem cell. The invention further provides a method for preparing a culture medium, a culture medium supplement and a composition comprising a compound of formula (I).

  该发明提供了一种可逆抑制干细胞分化的方法，其中将式(I)的化合物与干细胞接触。该发明还提供了一种制备培养基、培养基添加剂和包含式(I)化合物的组合物的方法。
• [EN] HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE KINASE RET
  申请人：CANCER RES TECH LTD

  公开号：WO2017178844A1

  公开（公告）日：2017-10-19

  The present invention relates to compounds of Formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, bonds a, b, c and d, X1, X2, X3, X4, R2, and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.

  本发明涉及具有以下结构的Formula I化合物，其作为RET（重排基因转座）激酶酶活性的抑制剂：其中HET，键a、b、c和d，X1、X2、X3、X4、R2和R3在此处各自定义。本发明还涉及制备这些化合物的方法，包括它们的药物组合物，以及它们在治疗增殖性疾病（如癌症）以及其他涉及RET激酶活性的疾病或症状中的用途。
• Heterocyclic compounds as RET kinase inhibitors
  申请人：Cancer Research Technology Limited

  公开号：US10844067B2

  公开（公告）日：2020-11-24

  The present invention relates to compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, X1, X2, X3, X4, integer a and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.

  本发明涉及作为 RET（转染过程中重排）激酶酶活性抑制剂的式 I 化合物： 其中HET、X1、X2、X3、X4、整数a和R3各自如本文所定义。本发明还涉及这些化合物的制备工艺、包含这些化合物的药物组合物，以及它们在治疗增殖性疾病（如癌症）和其他涉及 RET 激酶活性的疾病或病症中的用途。
• Heterocyclic compounds as ret kinase inhibitors
  申请人：Cancer Research Technology Limited

  公开号：US10954241B2

  公开（公告）日：2021-03-23

  The present invention relates to compounds of Formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: wherein HET, bonds a, b, c and d, X1, X2, X3, X4, R2, and R3 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.

  本发明涉及作为 RET（转染过程中重排）激酶酶活性抑制剂的式 I 化合物： 其中HET、键a、b、c和d、X1、X2、X3、X4、R2和R3各自如本文所定义。本发明还涉及这些化合物的制备工艺、包含这些化合物的药物组合物，以及它们在治疗增殖性疾病（如癌症）和其他涉及 RET 激酶活性的疾病或病症中的用途。